Neuropeptide systems and schizophrenia

CNS and Neurological Disorders - Drug Targets

Volumn 12, Issue 5, 2013, Pages 619-632

  LaCrosse, Amber L ^a   Olive, M Foster ^a  

^a ARIZONA STATE UNIVERSITY   (United States)

Author keywords

Antipsychotic; Cognitive deficits; Dopamine; Negative symptoms; Neuropeptide; Positive symptoms; Schizophrenia

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEXAMETHASONE; ENKEPHALIN; GAMMA ENDORPHIN; GI 181771; HALOPERIDOL; MECLINERTANT; MODAFINIL; NALOXONE; NALTREXONE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; NEUROPEPTIDE Y; NEUROTENSIN DERIVATIVE; NT 69L; OPIATE PEPTIDE; OSANETANT; OXYTOCIN; PHENCYCLIDINE DERIVATIVE; PLACEBO; PREPRODYNORPHIN; PREPROENKEPHALIN; PROTIRELIN DERIVATIVE; QUETIAPINE; RISPERIDONE; TACHYKININ; TALNETANT; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APPETITE DISORDER; ARTICLE; CEREBROSPINAL FLUID; DIABETES MELLITUS; DOPAMINE RELEASE; DRUG EFFICACY; DRUG TARGETING; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; HYPOTENSION; IMMUNOREACTIVITY; METABOLIC SYNDROME X; MONOAMINERGIC SYSTEM; MULTICENTER STUDY (TOPIC); NERVE CONDUCTION; NEUROTRANSMISSION; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN PHOSPHORYLATION; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOPHRENIA; SENSORIMOTOR CORTEX; SIDE EFFECT; SIGNAL TRANSDUCTION; WEIGHT GAIN;

EID: 84882764386     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527311312050010     Document Type: Article

References (208)

1. Messias, E.L.; Chen, C.Y.; Eaton, W.W. Epidemiology of schizophrenia: review of findings and myths. Psychiatr. Clin. North Am., 2007, 30, 323-338.
2. Green, M.F.; Kern, R.S.; Heaton, R.K. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr. Res., 2004, 72, 41-51.
3. Kurtz, M.M. Cognitive remediation for schizophrenia: current status, biological correlates and predictors of response. Exp. Rev. Neurother., 2012, 12, 813-821.
4. Meltzer, H.Y.; Stahl, S.M. The dopamine hypothesis of schizophrenia: a review. Schizophr. Bull., 1976, 2, 19-76.
5. Davis, K.L.; Kahn, R.S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiatry, 1991, 148, 1474-1486.
6. Howes, O.D.; Kapur, S. The dopamine hypothesis of schizophrenia: version III--the final common pathway. Schizophr. Bull., 2009, 35, 549-562.
7. Owens, D.G.C. A guide to the extrapyramidal side effects antipsychotic drugs. Cambridge University Press: Cambridge, 1999.
8. Meltzer, H.Y.; Matsubara, S.; Lee, J.C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther., 1989, 251, 238-246.
9. Schotte, A.; Janssen, P.F.; Gommeren, W.; Luyten, W.H.; Van Gompel, P.; Lesage, A.S.; De Loore, K.; Leysen, J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology, 1996, 124, 57-73.
10. Meyer, J.M.; Simpson, G.M. From chlorpromazine to olanzapine: a brief history of antipsychotics. Psychiatric Serv., 1997, 48, 1137-1139.
11. Lieberman, J.A.; Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Rosenheck, R.A.; Perkins, D.O.; Keefe, R.S.; Davis, S.M.; Davis, C.E.; Lebowitz, B.D.; Severe, J.; Hsiao, J.K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med., 2005, 353, 1209-1223.
12. Lieberman, J.A.; Stroup, T.S. The NIMH-CATIE Schizophrenia Study: what did we learn? Am. J. Psychiatry, 2011, 168, 770-775.
13. Stroup, T.S.; McEvoy, J.P.; Swartz, M.S.; Byerly, M.J.; Glick, I.D.; Canive, J.M.; McGee, M.F.; Simpson, G.M.; Stevens, M.C.; Lieberman, J.A. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol development. Schizophr. Bull., 2003, 29, 15-31.
14. Naber, D.; Lambert, M. The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs, 2009, 23, 649-659.
15. Jones, P.B.; Barnes, T.R.; Davies, L.; Dunn, G.; Lloyd, H.; Hayhurst, K.P.; Murray, R.M.; Markwick, A.; Lewis, S.W. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry, 2006, 63, 1079-1087.
16. Lewis, S.; Lieberman, J.A. CATIE and CUtLESS: can we handle the truth? Br. J. Psychiatry, 2008, 192, 161-163.
17. Lewis, S.W.; Barnes, T.R.; Davies, L.; Murray, R.M.; Dunn, G.; Hayhurst, K.P.; Markwick, A.; Lloyd, H.; Jones, P.B. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr. Bull., 2006, 32, 715-723.
18. McGonigle, P. Peptide therapeutics for CNS indications. Biochem Pharmacol, 2012, 83, 559-566.
19. Griebel, G.; Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat. Rev. Drug Discov., 2012, 11, 462-478.
20. Carraway, R.; Leeman, S.E. The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami. J. Biol. Chem., 1973, 248, 6854-6861.
21. St-Gelais, F.; Jomphe, C.; Trudeau, L.E. The role of neurotensin in central nervous system pathophysiology: what is the evidence? J. Psychiatry Neurosci., 2006, 31, 229-245.
22. Uhl, G.R.; Kuhar, M.J.; Snyder, S.H. Neurotensin: immunohistochemical localization in rat central nervous system. Proc. Natl. Acad. Sci. USA, 1977, 74, 4059-4063.
23. Uhl, G.R. Distribution of neurotensin and its receptor in the central nervous system. Ann. NY Acad. Sci., 1982, 400, 132-149.
24. Dobner, P.R. Multitasking with neurotensin in the central nervous system. Cell Mol. Life Sci., 2005, 62, 1946-1963.
25. Vincent, J.P.; Mazella, J.; Kitabgi, P. Neurotensin and neurotensin receptors. Trends Pharmacol. Sci., 1999, 20, 302-309.
26. Jomphe, C.; Lemelin, P.L.; Okano, H.; Kobayashi, K.; Trudeau, L.E. Bidirectional regulation of dopamine D2 and neurotensin NTS1 receptors in dopamine neurons. Eur. J. Neurosci., 2006, 24, 2789-2800.
27. Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. Neurotensin and dopamine interactions. Pharmacol. Rev., 2001, 53, 453-486.
28. Bean, A.J.; During, M.J.; Roth, R.H. Effects of dopamine autoreceptor stimulation on the release of colocalized transmitters: in vivo release of dopamine and neurotensin from rat prefrontal cortex. Neurosci. Lett., 1990, 108, 143-148.
29. Fassio, A.; Evans, G.; Grisshammer, R.; Bolam, J.P.; Mimmack, M.; Emson, P.C. Distribution of the neurotensin receptor NTS1 in the rat CNS studied using an amino-terminal directed antibody. Neuropharmacology, 2000, 39, 1430-1442.
30. Prus, A.J.; Huang, M.; Li, Z.; Dai, J.; Meltzer, H.Y. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Res., 2007, 1184, 354-364.
31. Dana, C.; Vial, M.; Leonard, K.; Beauregard, A.; Kitabgi, P.; Vincent, J.P.; Rostene, W.; Beaudet, A. Electron microscopic localization of neurotensin binding sites in the midbrain tegmentum of the rat. I. Ventral tegmental area and the interfascicular nucleus. J. Neurosci., 1989, 9, 2247-2257.
32. Nalivaiko, E.; Michaud, J.C.; Soubrie, P.; Le Fur, G. Electrophysiological evidence for putative subtypes of neurotensin receptors in guinea-pig mesencephalic dopaminergic neurons. Neuroscience, 1998, 86, 799-811.
33. Wu, T.; Wang, H.L. Protein kinase C mediates neurotensin inhibition of inwardly rectifying potassium currents in rat substantia nigra dopaminergic neurons. Neurosci. Lett., 1995, 184, 121-124.
34. Sotty, F.; Brun, P.; Leonetti, M.; Steinberg, R.; Soubrie, P.; Renaud, B.; Suaud-Chagny, M.F. Comparative effects of neurotensin, neurotensin(8-13) and [D-Tyr(11)]neurotensin applied into the ventral tegmental area on extracellular dopamine in the rat prefrontal cortex and nucleus accumbens. Neuroscience, 2000, 98, 485-492.
35. Kinkead, B.; Nemeroff, C.B. Novel treatments of schizophrenia: targeting the neurotensin system. CNS Neurol. Disord. Drug Targets, 2006, 5, 205-218.
36. Binder, E.B.; Kinkead, B.; Owens, M.J.; Nemeroff, C.B. The role of neurotensin in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic drugs. Biol. Psychiatry, 2001, 50, 856-872.
37. Garver, D.L.; Bissette, G.; Yao, J.K.; Nemeroff, C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry, 1991, 148, 484-488.
38. Breslin, N.A.; Suddath, R.L.; Bissette, G.; Nemeroff, C.B.; Lowrimore, P.; Weinberger, D.R. CSF concentrations of neurotensin in schizophrenia: an investigation of clinical and biochemical correlates. Schizophr. Res., 1994, 12, 35-41.
39. Kinkead, B.; Nemeroff, C.B. Neurotensin: an endogenous antipsychotic? Curr. Opin. Pharmacol., 2002, 2, 99-103.
40. Caceda, R.; Kinkead, B.; Nemeroff, C.B. Neurotensin: role in psychiatric and neurological diseases. Peptides, 2006, 27, 2385-2404.
41. Meltzer, H.Y.; Arvanitis, L.; Bauer, D.; Rein, W. Placebocontrolled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder. Am. J. Psychiatry, 2004, 161, 975-984.
42. Briody, S.; Boules, M.; Oliveros, A.; Fauq, I.; Richelson, E. Chronic NT69L potently prevents drug-induced disruption of prepulse inhibition without causing tolerance. Behav. Brain Res., 2010, 207, 118-124.
43. Richelson, E. NT69L: a neurotensin receptor agonist for treatment of neuropsychiatric diseases. Neuropsychopharmacology, 2005, 30, S50.
44. Hokfelt, T.; Morino, P.; Verge, V.; Castel, M.N.; Broberger, C.; Zhang, X.; Herrera-Marschitz, M.; Meana, J.J.; Ungerstedt, U.; Xu, X.J. et al. CCK in cerebral cortex and at the spinal level. Ann. NY Acad. Sci., 1994, 713, 157-163.
45. Lindefors, N.; Linden, A.; Brene, S.; Sedvall, G.; Persson, H. CCK peptides and mRNA in the human brain. Prog. Neurobiol., 1993, 40, 671-690.
46. Vanderhaeghen, J.J.; Lotstra, F.; Vierendeels, G.; Gilles, C.; Deschepper, C.; Verbanck, P. Cholecystokinins in the central nervous system and neurohypophysis. Peptides, 1981, 2(Suppl 2), 81-88.
47. Savasta, M.; Ruberte, E.; Palacios, J.M.; Mengod, G. The colocalization of cholecystokinin and tyrosine hydroxylase mRNAs in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridization. Neuroscience, 1989, 29, 363-369.
48. Palacios, J.M.; Savasta, M.; Mengod, G. Does cholecystokinin colocalize with dopamine in the human substantia nigra? Brain Res., 1989, 488, 369-375.
49. Schneider, L.H.; Alpert, J.E.; Iversen, S.D. CCK-8 modulation of mesolimbic dopamine: antagonism of amphetamine-stimulated behaviors. Peptides, 1983, 4, 749-753.
50. Vaccarino, F.J.; Rankin, J. Nucleus accumbens cholecystokinin (CCK) can either attenuate or potentiate amphetamine-induced locomotor activity: evidence for rostral-caudal differences in accumbens CCK function. Behav. Neurosci., 1989, 103, 831-836.
51. Tachikawa, H.; Harada, S.; Kawanishi, Y.; Okubo, T.; Suzuki, T. Linked polymorphisms (-333G>T and-286A>G) in the promoter region of the CCK-A receptor gene may be associated with schizophrenia. Psychiatry Res., 2001, 103, 147-155.
52. Garver, D.L.; Beinfeld, M.C.; Yao, J.K. Cholecystokinin, dopamine and schizophrenia. Psychopharmacol. Bull., 1990, 26, 377-380.
53. Lotstra, F.; Verbanck, P.M.; Gilles, C.; Mendlewicz, J.; Vanderhaeghen, J.J. Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Effect of ceruletide in schizophrenia. Ann. NY Acad. Sci., 1985, 448, 507-517.
54. Bachus, S.E.; Hyde, T.M.; Herman, M.M.; Egan, M.F.; Kleinman, J.E. Abnormal cholecystokinin mRNA levels in entorhinal cortex of schizophrenics. J. Psychiatr. Res., 1997, 31, 233-256.
55. Farmery, S.M.; Owen, F.; Poulter, M.; Crow, T.J. Reduced high affinity cholecystokinin binding in hippocampus and frontal cortex of schizophrenic patients. Life Sci., 1985, 36, 473-477.
56. Gabriel, S.M.; Davidson, M.; Haroutunian, V.; Powchik, P.; Bierer, L.M.; Purohit, D.P.; Perl, D.P.; Davis, K.L. Neuropeptide deficits in schizophrenia vs Alzheimer's disease cerebral cortex. Biol. Psychiatry, 1996, 39, 82-91.
57. Nair, N.P.; Lal, S.; Bloom, D.M. Cholecystokinin and schizophrenia. Prog Brain Res, 1986, 65, 237-258.
58. Montgomery, S.A.; Green, M.C. The use of cholecystokinin in schizophrenia: a review. Psychol. Med., 1988, 18, 593-603.
59. Albus, M.; von Gellhorn, K.; Munch, U.; Naber, D.; Ackenheil, M. A double-blind study with ceruletide in chronic schizophrenic patients: biochemical and clinical results. Psychiatry Res., 1986, 19, 1-7.
60. Tamminga, C.A.; Littman, R.L.; Alphs, L.D.; Chase, T.N.; Thaker, G.K.; Wagman, A.M. Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology, 1986, 88, 387-391.
61. Caceda, R.; Kinkead, B.; Nemeroff, C.B. Involvement of neuropeptide systems in schizophrenia: human studies. Int. Rev. Neurobiol., 2007, 78, 327-376.
62. Szewczyk, J.R.; Laudeman, C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr. Top. Med. Chem., 2003, 3, 837-854.
63. Koefoed, P.; Hansen, T.V.; Woldbye, D.P.; Werge, T.; Mors, O.; Hansen, T.; Jakobsen, K.D.; Nordentoft, M.; Wang, A.; Bolwig, T.G.; Rehfeld, J.F. An intron 1 polymorphism in the cholecystokinin-A receptor gene associated with schizophrenia in males. Acta Psychiatr. Scand., 2009, 120, 281-287.
64. Bale, T.L.; Vale, W.W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol., 2004, 44, 525-557.
65. Binder, E.B.; Nemeroff, C.B. The CRF system, stress, depression and anxiety-insights from human genetic studies. Mol. Psychiatry, 2010, 15, 574-588.
66. Lloyd, R.B.; Nemeroff, C.B. The role of corticotropin-releasing hormone in the pathophysiology of depression: therapeutic implications. Curr. Top. Med. Chem., 2011, 11, 609-617.
67. Ressler, K.J.; Nemeroff, C.B. Peptides and Psychiatry. In: Encyclopedia of Social and Behavioral Science, Smelser, N.J., Baltes, P.B., Eds.; Elsevier: London; 2001, pp. 11189-11195.
68. Banki, C.M.; Bissette, G.; Arato, M.; O'Connor, L.; Nemeroff, C.B. CSF corticotropin-releasing factor-like immunoreactivity in depression and schizophrenia. Am. J. Psychiatry, 1987, 144, 873-877.
69. Nishino, S.; Mignot, E.; Benson, K.L.; Zarcone, V.P., Jr. Cerebrospinal fluid prostaglandins and corticotropin releasing factor in schizophrenics and controls: relationship to sleep architecture. Psychiatry Res., 1998, 78, 141-150.
70. Forman, S.D.; Bissette, G.; Yao, J.; Nemeroff, C.B.; van Kammen, D.P. Cerebrospinal fluid corticotropin-releasing factor increases following haloperidol withdrawal in chronic schizophrenia. Schizophr. Res., 1994, 12, 43-51.
71. Nikisch, G.; Baumann, P.; Liu, T.; Mathe, A.A. Quetiapine affects neuropeptide Y and corticotropin-releasing hormone in cerebrospinal fluid from schizophrenia patients: relationship to depression and anxiety symptoms and to treatment response. Int. J. Neuropsychopharmacol., 2012, 15, 1051-1061.
72. Frederiksen, S.O.; Ekman, R.; Gottfries, C.G.; Widerlov, E.; Jonsson, S. Reduced concentrations of galanin, arginine vasopressin, neuropeptide Y and peptide YY in the temporal cortex but not in the hypothalamus of brains from schizophrenics. Acta Psychiatr. Scand., 1991, 83, 273-277.
73. Herringa, R.J.; Roseboom, P.H.; Kalin, N.H. Decreased amygdala CRF-binding protein mRNA in post-mortem tissue from male but not female bipolar and schizophrenic subjects. Neuropsychopharmacology, 2006, 31, 1822-1831.
74. Yeap, S.; Thakore, J.H. Stress axis dysfunction in schizophrenia. Eur. Psychiatry, 2005, 20(Suppl 3), S307-312.
75. Walker, E.; Mittal, V.; Tessner, K. Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Ann. Rev. Clin. Psychol., 2008, 4, 189-216.
76. Newcomer, J.W.; Faustman, W.O.; Whiteford, H.A.; Moses, J.A., Jr.; Csernansky, J.G. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol. Psychiatry, 1991, 29, 855-864.
77. Tandon, R.; Mazzara, C.; DeQuardo, J.; Craig, K.A.; Meador-Woodruff, J.H.; Goldman, R.; Greden, J.F. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol. Psychiatry, 1991, 29, 953-964.
78. Kaneko, M.; Yokoyama, F.; Hoshino, Y.; Takahagi, K.; Murata, S.; Watanabe, M.; Kumashiro, H. Hypothalamic-pituitary-adrenal axis function in chronic schizophrenia: association with clinical features. Neuropsychobiology, 1992, 25, 1-7.
79. Altamura, C.; Guercetti, G.; Percudani, M. Dexamethasone suppression test in positive and negative schizophrenia. Psychiatry Res., 1989, 30, 69-75.
80. Coryell, W.; Tsuang, D. Hypothalamic-pituitary-adrenal axis hyperactivity and psychosis: recovery during an 8-year follow-up. Am. J. Psychiatry, 1992, 149, 1033-1039.
81. Lammers, C.H.; Garcia-Borreguero, D.; Schmider, J.; Gotthardt, U.; Dettling, M.; Holsboer, F.; Heuser, I.J. Combined dexamethasone/corticotropin-releasing hormone test in patients with schizophrenia and in normal controls: II. Biol. Psychiatry, 1995, 38, 803-807.
82. Chronwall, B.M.; DiMaggio, D.A.; Massari, V.J.; Pickel, V.M.; Ruggiero, D.A.; O'Donohue, T.L. The anatomy of neuropeptide-Ycontaining neurons in rat brain. Neuroscience, 1985, 15, 1159-1181.
83. Benarroch, E.E. Neuropeptide Y: its multiple effects in the CNS and potential clinical significance. Neurology, 2009, 72, 1016-1020.
84. Thorsell, A. Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Exp. Biol. Med., 2010, 235, 1163-1167.
85. Karl, T.; Herzog, H. Behavioral profiling of NPY in aggression and neuropsychiatric diseases. Peptides, 2007, 28, 326-333.
86. Eaton, K.; Sallee, F.R.; Sah, R. Relevance of neuropeptide Y (NPY) in psychiatry. Curr. Top. Med. Chem., 2007, 7, 1645-1659.
87. Widerlov, E.; Lindstrom, L.H.; Wahlestedt, C.; Ekman, R. Neuropeptide Y and peptide YY as possible cerebrospinal fluid markers for major depression and schizophrenia, respectively. J. Psychiatr. Res., 1988, 22, 69-79.
88. Peters, J.; Van Kammen, D.P.; Gelernter, J.; Yao, J.; Shaw, D. Neuropeptide Y-like immunoreactivity in schizophrenia. Relationships with clinical measures. Schizophr. Res., 1990, 3, 287-294.
89. Itokawa, M.; Arai, M.; Kato, S.; Ogata, Y.; Furukawa, A.; Haga, S.; Ujike, H.; Sora, I.; Ikeda, K.; Yoshikawa, T. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci. Lett., 2003, 347, 202-204.
90. Detera-Wadleigh, S.D.; de Miguel, C.; Berrettini, W.H.; DeLisi, L.E.; Goldin, L.R.; Gershon, E.S. Neuropeptide gene polymorphisms in affective disorder and schizophrenia. J. Psychiatr. Res., 1987, 21, 581-587.
91. Duan, S.; Gao, R.; Xing, Q.; Du, J.; Liu, Z.; Chen, Q.; Wang, H.; Feng, G.; He, L. A family-based association study of schizophrenia with polymorphisms at three candidate genes. Neurosci. Lett., 2005, 379, 32-36.
92. Lindberg, C.; Koefoed, P.; Hansen, E.S.; Bolwig, T.G.; Rehfeld, J.F.; Mellerup, E.; Jorgensen, O.S.; Kessing, L.V.; Werge, T.; Haugbol, S.; Wang, A.G.; Woldbye, D.P. No association between the-399C>T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population. Acta Psychiatr. Scand., 2006, 113, 54-58.
93. Kuromitsu, J.; Yokoi, A.; Kawai, T.; Nagasu, T.; Aizawa, T.; Haga, S.; Ikeda, K. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Brain Res. Gene Expr. Patterns, 2001, 1, 17-21.
94. Choi, K.H.; Elashoff, M.; Higgs, B.W.; Song, J.; Kim, S.; Sabunciyan, S.; Diglisic, S.; Yolken, R.H.; Knable, M.B.; Torrey, E.F.; Webster, M.J. Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry, 2008, 8, 87.
95. Ikeda, K.; Ikeda, K.; Iritani, S.; Ueno, H.; Niizato, K. Distribution of neuropeptide Y interneurons in the dorsal prefrontal cortex of schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2004, 28, 379-383.
96. Beal, M.F.; Svendsen, C.N.; Bird, E.D.; Martin, J.B. Somatostatin and neuropeptide Y are unaltered in the amygdala in schizophrenia. Neurochem. Pathol., 1987, 6, 169-176.
97. Iritani, S.; Kuroki, N.; Niizato, K.; Ikeda, K. Morphological changes in neuropeptide Y-positive fiber in the hippocampal formation of schizophrenics. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2000, 24, 241-249.
98. Obuchowicz, E.; Krysiak, R.; Herman, Z.S. Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs? Neurosci. Biobehav. Rev., 2004, 28, 595-610.
99. Sakai, K.; Maeda, K.; Chihara, K.; Kaneda, H. Increases in cortical neuropeptide Y and somatostatin concentrations following haloperidol-depot treatment in rats. Neuropeptides, 1995, 29, 157-161.
100. Midgley, L.P.; Bush, L.G.; Gibb, J.W.; Hanson, G.R. Characterization of phencyclidine-induced effects on neuropeptide Y systems in the rat caudate-putamen. Brain Res., 1992, 593, 89-96.
101. Vawter, M.P.; Ferran, E.; Galke, B.; Cooper, K.; Bunney, W.E.; Byerley, W. Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr. Res., 2004, 67, 41-52.
102. Caberlotto, L.; Hurd, Y.L. Neuropeptide Y Y1 and Y2 receptor mRNA expression in the prefrontal cortex of psychiatric subjects. Relationship of Y2 subtype to suicidal behavior. Neuropsychopharmacology, 2001, 25, 91-97.
103. Karl, T.; Chesworth, R.; Duffy, L.; Herzog, H. Acoustic startle response and sensorimotor gating in a genetic mouse model for the Y1 receptor. Neuropeptides, 2010, 44, 233-239.
104. Karl, T.; Chesworth, R.; Duffy, L.; Herzog, H. Schizophreniarelevant behaviours in a genetic mouse model for Y2 deficiency. Behav. Brain Res., 2010, 207, 434-440.
105. Brothers, S.P.; Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) receptor ligands. EMBO Mol. Med., 2010, 2, 429-439.
106. Murphy, D.; Konopacka, A.; Hindmarch, C.; Paton, J.F.; Sweedler, J.V.; Gillette, M.U.; Ueta, Y.; Grinevich, V.; Lozic, M.; Japundzic-Zigon, N. The hypothalamic-neurohypophyseal system: from genome to physiology. J. Neuroendocrinol., 2012, 24, 539-553.
107. Marazziti, D.; Catena, D.O.M. The role of oxytocin in neuropsychiatric disorders. Curr. Med. Chem., 2008, 15, 698-704.
108. Beckmann, H.; Lang, R.E.; Gattaz, W.F. Vasopressin-oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. Psychoneuroendocrinology, 1985, 10, 187-191.
109. Goldman, M.; Marlow-O'Connor, M.; Torres, I.; Carter, C.S. Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits. Schizophr. Res., 2008, 98, 247-255.
110. Glovinsky, D.; Kalogeras, K.T.; Kirch, D.G.; Suddath, R.; Wyatt, R.J. Cerebrospinal fluid oxytocin concentration in schizophrenic patients does not differ from control subjects and is not changed by neuroleptic medication. Schizophr. Res., 1994, 11, 273-276.
111. Sasayama, D.; Hattori, K.; Teraishi, T.; Hori, H.; Ota, M.; Yoshida, S.; Arima, K.; Higuchi, T.; Amano, N.; Kunugi, H. Negative correlation between cerebrospinal fluid oxytocin levels and negative symptoms of male patients with schizophrenia. Schizophr. Res., 2012, 139, 201-206.
112. Keri, S.; Kiss, I.; Kelemen, O. Sharing secrets: oxytocin and trust in schizophrenia. Social Neurosci., 2009, 4, 287-293.
113. Rubin, L.H.; Carter, C.S.; Drogos, L.; Pournajafi-Nazarloo, H.; Sweeney, J.A.; Maki, P.M. Peripheral oxytocin is associated with reduced symptom severity in schizophrenia. Schizophr. Res., 2010, 124, 13-21.
114. Teltsh, O.; Kanyas-Sarner, K.; Rigbi, A.; Greenbaum, L.; Lerer, B.; Kohn, Y. Oxytocin and vasopressin genes are significantly associated with schizophrenia in a large Arab-Israeli pedigree. Int. J. Neuropsychopharmacol., 2011, in press.
115. Montag, C.; Brockmann, E.M.; Bayerl, M.; Rujescu, D.; Muller, D.J.; Gallinat, J. Oxytocin and oxytocin receptor gene polymorphisms and risk for schizophrenia: A case-control study. World J. Biol. Psychiatry, 2012, in press.
116. Souza, R.P.; de Luca, V.; Meltzer, H.Y.; Lieberman, J.A.; Kennedy, J.L. Schizophrenia severity and clozapine treatment outcome association with oxytocinergic genes. Int. J. Neuropsychopharmacol., 2010, 13, 793-798.
117. Bujanow, W. Letter: Is oxytocin an anti-schizophrenic hormone? Can Psychiatr Assoc J, 1974, 19, 323.
118. Feifel, D.; Reza, T. Oxytocin modulates psychotomimetic-induced deficits in sensorimotor gating. Psychopharmacology, 1999, 141, 93-98.
119. Caldwell, H.K.; Stephens, S.L.; Young, W.S. d. Oxytocin as a natural antipsychotic: a study using oxytocin knockout mice. Mol. Psychiatry, 2009, 14, 190-196.
120. Striepens, N.; Kendrick, K.M.; Maier, W.; Hurlemann, R. Prosocial effects of oxytocin and clinical evidence for its therapeutic potential. Front. Neuroendocrinol., 2011, 32, 426-450.
121. Rosenfeld, A.J.; Lieberman, J.A.; Jarskog, L.F. Oxytocin, dopamine, and the amygdala: a neurofunctional model of social cognitive deficits in schizophrenia. Schizophr. Bull., 2011, 37, 1077-1087.
122. Lee, P.R.; Brady, D.L.; Shapiro, R.A.; Dorsa, D.M.; Koenig, J.I. Social interaction deficits caused by chronic phencyclidine administration are reversed by oxytocin. Neuropsychopharmacology, 2005, 30, 1883-1894.
123. Averbeck, B.B.; Bobin, T.; Evans, S.; Shergill, S.S. Emotion recognition and oxytocin in patients with schizophrenia. Psychol. Med., 2011, in press.
124. Pedersen, C.A.; Gibson, C.M.; Rau, S.W.; Salimi, K.; Smedley, K.L.; Casey, R.L.; Leserman, J.; Jarskog, L.F.; Penn, D.L. Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia. Schizophr. Res., 2011, 132, 50-53.
125. Feifel, D.; Macdonald, K.; Cobb, P.; Minassian, A. Adjunctive intranasal oxytocin improves verbal memory in people with schizophrenia. Schizophr. Res., 2012, 139, 207-210.
126. Feifel, D.; Macdonald, K.; Nguyen, A.; Cobb, P.; Warlan, H.; Galangue, B.; Minassian, A.; Becker, O.; Cooper, J.; Perry, W.; Lefebvre, M.; Gonzales, J.; Hadley, A. Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients. Biol. Psychiatry, 2010, 68, 678-680.
127. Feifel, D. Is oxytocin a promising treatment for schizophrenia? Exp. Rev. Neurother., 2011, 11, 157-159.
128. Macdonald, K.; Feifel, D. Oxytocin in schizophrenia: a review of evidence for its therapeutic effects. Acta Neuropsychiatry, 2012, 24, 130-146.
129. Mansour, A.; Khachaturian, H.; Lewis, M.E.; Akil, H.; Watson, S.J. Anatomy of CNS opioid receptors. Trends Neurosci., 1988, 11, 308-314.
130. Terenius, L. From opiate pharmacology to opioid peptide physiology. Ups J Med Sci, 2000, 105, 1-15.
131. Mikesell, M.J.; Sobell, J.L.; Sommer, S.S.; McMurray, C.T. Identification of a missense mutation and several polymorphisms in the proenkephalin A gene of schizophrenic patients. Am. J. Med. Genet., 1996, 67, 459-467.
132. Mikesell, M.J.; Barron, Y.D.; Nimgaonkar, V.L.; Sobell, J.L.; Sommer, S.S.; McMurray, C.T. Gly(247)->Asp proenkephalin A mutation is rare in schizophrenia populations. Am. J. Med. Genet., 1997, 74, 213-215.
133. Zhang, C.S.; Tan, Z.; Lu, L.; Wu, S.N.; He, Y.; Gu, N.F.; Feng, G.Y.; He, L. Polymorphism of prodynorphin promoter is associated with schizophrenia in Chinese population. Acta Pharmacol. Sin., 2004, 25, 1022-1026.
134. Ventriglia, M.; Bocchio Chiavetto, L.; Bonvicini, C.; Tura, G.B.; Bignotti, S.; Racagni, G.; Gennarelli, M. Allelic variation in the human prodynorphin gene promoter and schizophrenia. Neuropsychobiology, 2002, 46, 17-21.
135. Bernstein, H.G.; Krell, D.; Emrich, H.M.; Baumann, B.; Danos, P.; Diekmann, S.; Bogerts, B. Fewer beta-endorphin expressing arcuate nucleus neurons and reduced beta-endorphinergic innervation of paraventricular neurons in schizophrenics and patients with depression. Cell Mol. Biol., 2002, 48, OL259-OL265.
136. Volk, D.W.; Radchenkova, P.V.; Walker, E.M.; Sengupta, E.J.; Lewis, D.A. Cortical opioid markers in schizophrenia and across postnatal development. Cereb. Cortex, 2012, 22, 1215-1223.
137. Tanaka, S.; Matsunaga, H.; Kimura, M.; Tatsumi, K.; Hidaka, Y.; Takano, T.; Uema, T.; Takeda, M.; Amino, N. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J. Neuroimmunol., 2003, 141, 155-164.
138. Peckys, D.; Hurd, Y.L. Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders. Brain Res. Bull., 2001, 55, 619-624.
139. Mosnaim, A.D.; Nguyen, T.D.; Puente, J.; Wolf, M.E. Degradation kinetics of methionine5-enkephalin by select brain areas from patients with chronic schizophrenia. Am. J. Ther., 2008, 15, 126-130.
140. Azorin, J.M.; Blum, A.; Charbaut, J.; Escande, M.; Granier, F.; Huber, J.P.; Metzger, J.Y.; Richou, H.; Sitsen, A.; Van Amerongen, P.; Dufour, H. Des-enkephalin-γ-endorphin in the treatment of schizophrenia. Int. Clin. Psychopharmacol., 1990, 5, 205-215.
141. de Jongh, B.M.; Verhoeven, W.M.; van Ree, J.M.; de Wied, D.; van Rood, J.J. HLA, and the response to treatment with gammatype endorphins in schizophrenia. J. Immunogenet., 1982, 9, 381-388.
142. Wiegant, V.M.; Ronken, E.; Kovacs, G.; De Wied, D. Endorphins and schizophrenia. Prog. Brain Res., 1992, 93, 433-453.
143. Verhoeven, W.M.; van Praag, H.M.; van Ree, J. M.; de Wied, D. Improvement of schizophrenic patients treated with [des-Tyr1]-γ-endorphin (DTγE). Arch. Gen. Psychiatry, 1979, 36, 294-298.
144. Verhoeven, W.M.; van Ree, J.M.; Westenberg, H.G.; Krul, J.M.; Brouwer, G.J.; Thijssen, J.H.; de Wied, D.; van Praag, H.M.; Ceulemans, D.L.; Kahn, R.S. Clinical, biochemical, and hormonal aspects of treatment with Des-tyr1-gamma-endorphin in schizophrenia. Psychiatr. Res., 1984, 11, 329-346.
145. Montgomery, S.A.; Green, M.; Rimon, R.; Heikkila, L.; Forsstrom, R.; Hirsch, S.R.; Hallstrom, C.; Hippius, H.; Naber, R.; Khan, M.C. Inadequate treatment response to des-enkephalin-γ-endorphin compared with thioridazine and placebo in schizophrenia. Acta Psychiatr. Scand., 1992, 86, 97-103.
146. Janowsky, D.S.; Segal, D.S.; Abrams, A.; Bloom, F.; Guillemin, R. Negative naloxone effects in schizophrenic patients. Psychopharmacology, 1977, 53, 295-297.
147. Janowsky, D.S.; Segal, D.S.; Bloom, F.; Abrams, A.; Guillemin, R. Lack of effect on naloxone on schizophrenic symptoms. Am. J. Psychiatry, 1977, 134, 926-927.
148. Welch, E.B.; Thompson, D.F. Opiate antagonists for the treatment of schizophrenia. J. Clin. Pharm. Ther., 1994, 19, 279-283.
149. Almeida, T.A.; Rojo, J.; Nieto, P.M.; Pinto, F.M.; Hernandez, M.; Martin, J.D.; Candenas, M.L. Tachykinins and tachykinin receptors: structure and activity relationships. Curr. Med. Chem., 2004, 11, 2045-2081.
150. Helke, C.J.; Krause, J.E.; Mantyh, P.W.; Couture, R.; Bannon, M.J. Diversity in mammalian tachykinin peptidergic neurons: multiple peptides, receptors, and regulatory mechanisms. FASEB J., 1990, 4, 1606-1615.
151. Heikkila, L.; Rimon, R.; Terenius, L. Dynorphin A and substance P in the cerebrospinal fluid of schizophrenic patients. Psychiatry Res., 1990, 34, 229-236.
152. Miller, C.; Kirchmair, R.; Troger, J.; Saria, A.; Fleischhacker, W.W.; Fischer-Colbrie, R.; Benzer, A.; Winkler, H. CSF of neuroleptic-naive first-episode schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from chromogranin A (GE-25) and secretogranin II (secretoneurin). Biol. Psychiatry, 1996, 39, 911-918.
153. Rimon, R.; Le Greves, P.; Nyberg, F.; Heikkila, L.; Salmela, L.; Terenius, L. Elevation of substance P-like peptides in the CSF of psychiatric patients. Biol. Psychiatry, 1984, 19, 509-516.
154. Roberts, G.W.; Ferrier, I.N.; Lee, Y.; Crow, T.J.; Johnstone, E.C.; Owens, D.G.; Bacarese-Hamilton, A.J.; McGregor, G.; O'Shaughnessey, D.; Polak, J.M.; Bloom, S.R. Peptides, the limbic lobe and schizophrenia. Brain Res., 1983, 288, 199-211.
155. Toru, M.; Watanabe, S.; Shibuya, H.; Nishikawa, T.; Noda, K.; Mitsushio, H.; Ichikawa, H.; Kurumaji, A.; Takashima, M.; Mataga, N. et al. Neurotransmitters, receptors and neuropeptides in post-mortem brains of chronic schizophrenic patients. Acta Psychiatr. Scand., 1988, 78, 121-137.
156. Carletti, R.; Corsi, M.; Melotto, S.; Caberlotto, L. Down-regulation of amygdala preprotachykinin A mRNA but not 3H-SP receptor binding sites in subjects affected by mood disorders and schizophrenia. Eur. J. Neurosci., 2005, 21, 1712-1718.
157. Tooney, P.A.; Crawter, V.C.; Chahl, L.A. Increased tachykinin NK1 receptor immunoreactivity in the prefrontal cortex in schizophrenia. Biol. Psychiatry, 2001, 49, 523-527.
158. Spooren, W.; Riemer, C.; Meltzer, H. NK3 receptor antagonists: the next generation of antipsychotics? Nat. Rev. Drug Discov., 2005, 4, 967-975.
159. Dawson, L.A.; Smith, P.W. Therapeutic utility of NK3 receptor antagonists for the treatment of schizophrenia. Curr. Pharm. Design, 2010, 16, 344-357.
160. Evangelista, S. Talnetant GlaxoSmithKline. Curr. Opin. Invest. Drugs, 2005, 6, 717-721.
161. Simonsen, K.B.; Juhl, K.; Steiniger-Brach, B.; Nielsen, S.M. Novel NK3 receptor antagonists for the treatment of schizophrenia and other CNS indications. Curr. Opin. Drug Discov. Devel., 2010, 13, 379-388.
162. Rupniak, N.M.; Kramer, M.S. Discovery of the antidepressant and anti-emetic efficacy of substance P receptor (NK1) antagonists. Trends Pharmacol. Sci., 1999, 20, 485-490.
163. Yarbrough, G.G.; Kamath, J.; Winokur, A.; Prange, A.J.J. Thyrotropin-releasing hormone (TRH) in the neuroaxis: therapeutic effects reflect physiological functions and molecular actions. Med. Hypotheses, 2007, 69, 1249-1256.
164. Prokai, L. Central nervous system effects of thyrotropin-releasing hormone and its analogues: opportunities and perspectives for drug discovery and development. Prog. Drug Res., 2002, 59, 133-169.
165. Banki, C.M.; Karmacsi, L.; Bissette, G.; Nemeroff, C.B. Cerebrospinal-fluid neuropeptides: a biochemical subgrouping approach. Neuropsychobiology, 1992, 26, 37-42.
166. Sharma, R.P.; Martis, B.; Rosen, C.; Jonalagadda, J.; Nemeroff, C.B.; Bissette, G. CSF thyrotropin-releasing hormone concentrations differ in patients with schizoaffective disorder from patients with schizophrenia or mood disorders. J. Psychiatr. Res., 2001, 35, 287-291.
167. Biggins, J.A.; Perry, E.K.; McDermott, J.R.; Smith, A.I.; Perry, R.H.; Edwardson, J.A. Post mortem levels of thyrotropin-releasing hormone and neurotensin in the amygdala in Alzheimer's disease, schizophrenia and depression. J. Neurol. Sci., 1983, 58, 117-122.
168. Nemeroff, C.B.; Youngblood, W.W.; Manberg, P.J.; Prange, A.J.J.; Kizer, J.S. Regional brain concentrations of neuropeptides in Huntington's chorea and schizophrenia. Science, 1983, 221, 972-975.
169. Bigelow, L.B.; Gillin, J.C.; Semal, C.; Wyatt, R.J. Letter: Thyrotropin-releasing hormone in chronic schizophrenia. Lancet, 1975, 2, 869-870.
170. Davis, K.L.; Hossister, L.E.; Berger, P.A. Thyrotropin-releasing hormone in schizophrenia. Am. J. Psychiatry, 1975, 132, 951-953.
171. Lindstrom, L.H.; Gunne, L.M.; Ost, L.G.; Persson, E. Thyrotropinreleasing hormone (TRH) inchronic schizophrenia. A controlled study. Acta Psychiatr. Scand., 1977, 55, 74-80.
172. Kobayashi, K.; Nakaoka, K.; Tsuji, H.; Shohmori, T. Effects of thyrotropin-releasing hormone in chronic schizophrenic patients. Acta Med. Okayama, 1980, 34, 263-273.
173. Brambilla, F.; Aguglia, E.; Massironi, R.; Maggioni, M.; Grillo, W.; Castiglioni, R.; Catalano, M.; Drago, F. Neuropeptide therapies in chronic schizophrenia: TRH and vasopressin administration. Neuropsychobiology, 1986, 15, 114-121.
174. Mizuki, Y.; Nishikori, S.; Kajimura, N.; Imaizumi, J.; Yamada, M.; Inanaga, K. A treatment trial with an analog of thyrotropinreleasing hormone (DN-1417) in schizophrenia. Biol. Psychiatry, 1985, 20, 1030-1035.
175. Khomane, K.S.; Meena, C.L.; Jain, R.; Bansal, A.K. Novel thyrotropin-releasing hormone analogs: a patent review. Expert Opin. Ther. Pat., 2011, 21, 1673-1691.
176. Sakurai, T.; Mieda, M. Connectomics of orexin-producing neurons: interface of systems of emotion, energy homeostasis and arousal. Trends Pharmacol. Sci., 2011, 32, 451-462.
177. Thompson, J.L.; Borgland, S.L. A role for hypocretin/orexin in motivation. Behav. Brain Res., 2011, 217, 446-453.
178. Berridge, C.W.; Espana, R.A.; Vittoz, N.M. Hypocretin/orexin in arousal and stress. Brain Res., 2010, 1314, 91-102.
179. Peyron, C.; Tighe, D.K.; van den Pol, A.N.; de Lecea, L.; Heller, H.C.; Sutcliffe, J.G.; Kilduff, T.S. Neurons containing hypocretin (orexin) project to multiple neuronal systems. J. Neurosci., 1998, 18, 9996-10015.
180. Fadel, J.; Deutch, A.Y. Anatomical substrates of orexin-dopamine interactions: lateral hypothalamic projections to the ventral tegmental area. Neuroscience, 2002, 111, 379-387.
181. Borgland, S.L.; Ungless, M.A.; Bonci, A. Convergent actions of orexin/hypocretin and CRF on dopamine neurons: Emerging players in addiction. Brain Res., 2010, 1314, 139-144.
182. Vittoz, N.M.; Berridge, C.W. Hypocretin/orexin selectively increases dopamine efflux within the prefrontal cortex: Involvement of the ventral tegmental area. Neuropsychopharmacology, 2006, 31, 384-395.
183. Mori, K.; Kim, J.; Sasaki, K. Electrophysiological effects of orexin-B and dopamine on rat nucleus accumbens shell neurons in vitro. Peptides, 2011, 32, 246-252.
184. Govindaiah, G.; Cox, C.L. Modulation of thalamic neuron excitability by orexins. Neuropharmacology, 2006, 51, 414-425.
185. Choi, D.L.; Davis, J.F.; Magrisso, I.J.; Fitzgerald, M.E.; Lipton, J.W.; Benoit, S.C. Orexin signaling in the paraventricular thalamic nucleus modulates mesolimbic dopamine and hedonic feeding in the rat. Neuroscience, 2012, 210, 243-248.
186. Deutch, A.Y.; Bubser, M. The orexins/hypocretins and schizophrenia. Schizophr. Bull., 2007, 33, 1277-1283.
187. Fadel, J.; Bubser, M.; Deutch, A.Y. Differential activation of orexin neurons by antipsychotic drugs associated with weight gain. J. Neurosci., 2002, 22, 6742-6746.
188. Dalal, M.A.; Schuld, A.; Pollmacher, T. Lower CSF orexin A (hypocretin-1) levels in patients with schizophrenia treated with haloperidol compared to unmedicated subjects. Mol. Psychiatry, 2003, 8, 836-837.
189. Minzenberg, M.J.; Carter, C.S. Modafinil: a review of neurochemical actions and effects on cognition. Neuropsychopharmacology, 2008, 33, 1477-1502.
190. Lin, J.S.; Hou, Y.; Jouvet, M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl. Acad. Sci. USA, 1996, 93, 14128-14133.
191. Scammell, T.E.; Estabrooke, I.V.; McCarthy, M.T.; Chemelli, R.M.; Yanagisawa, M.; Miller, M.S.; Saper, C.B. Hypothalamic arousal regions are activated during modafinil-induced wakefulness. J. Neurosci., 2000, 20, 8620-8628.
192. Morein-Zamir, S.; Turner, D.C.; Sahakian, B.J. A review of the effects of modafinil on cognition in schizophrenia. Schizophr. Bull., 2007, 33, 1298-1306.
193. Saavedra-Velez, C.; Yusim, A.; Anbarasan, D.; Lindenmayer, J.P. Modafinil as an adjunctive treatment of sedation, negative symptoms, and cognition in schizophrenia: a critical review. J. Clin. Psychiatry, 2009, 70, 104-112.
194. Barch, D.M. Pharmacological strategies for enhancing cognition in schizophrenia. Curr. Top. Behav. Neurosci., 2010, 4, 43-96.
195. Scoriels, L.; Jones, P.B.; Sahakian, B.J. Modafinil effects on cognition and emotion in schizophrenia and its neurochemical modulation in the brain. Neuropharmacology, 2012, in press.
196. Rosenthal, M.H.; Bryant, S.L. Benefits of adjunct modafinil in an open-label, pilot study in patients with schizophrenia. Clin. Neuropharmacol., 2004, 27, 38-43.
197. Turner, D.C.; Clark, L.; Pomarol-Clotet, E.; McKenna, P.; Robbins, T.W.; Sahakian, B.J. Modafinil improves cognition and attentional set shifting in patients with chronic schizophrenia. Neuropsychopharmacology, 2004, 29, 1363-1373.
198. Pierre, J.M.; Peloian, J.H.; Wirshing, D.A.; Wirshing, W.C.; Marder, S.R. A randomized, double-blind, placebo-controlled trial of modafinil for negative symptoms in schizophrenia. J. Clin. Psychiatry, 2007, 68, 705-710.
199. Arbabi, M.; Bagheri, M.; Rezaei, F.; Ahmadi-Abhari, S.A.; Tabrizi, M.; Khalighi-Sigaroudi, F.; Akhondzadeh, S. A placebo-controlled study of the modafinil added to risperidone in chronic schizophrenia. Psychopharmacology, 2012, 220, 591-598.
200. Scoriels, L.; Barnett, J.H.; Murray, G.K.; Cherukuru, S.; Fielding, M.; Cheng, F.; Lennox, B.R.; Sahakian, B.J.; Jones, P.B. Effects of modafinil on emotional processing in first episode psychosis. Biol. Psychiatry, 2011, 69, 457-464.
201. Sevy, S.; Rosenthal, M.H.; Alvir, J.; Meyer, S.; Visweswaraiah, H.; Gunduz-Bruce, H.; Schooler, N.R. Double-blind, placebocontrolled study of modafinil for fatigue and cognition in schizophrenia patients treated with psychotropic medications. J. Clin. Psychiatry, 2005, 66, 839-843.
202. Freudenreich, O.; Henderson, D.C.; Macklin, E.A.; Evins, A.E.; Fan, X.; Cather, C.; Walsh, J.P.; Goff, D.C. Modafinil for clozapine-treated schizophrenia patients: a double-blind, placebocontrolled pilot trial. J. Clin. Psychiatry, 2009, 70, 1674-1680.
203. Hunter, M.D.; Ganesan, V.; Wilkinson, I.D.; Spence, S.A. Impact of modafinil on prefrontal executive function in schizophrenia. Am. J. Psychiatry, 2006, 163, 2184-2186.
204. Spence, S.A.; Green, R.D.; Wilkinson, I.D.; Hunter, M.D. Modafinil modulates anterior cingulate function in chronic schizophrenia. Br. J. Psychiatry, 2005, 187, 55-61.
205. Kane, J.M.; D'Souza, D.C.; Patkar, A.A.; Youakim, J.M.; Tiller, J.M.; Yang, R.; Keefe, R.S. Armodafinil as adjunctive therapy in adults with cognitive deficits associated with schizophrenia: a 4-week, double-blind, placebo-controlled study. J. Clin. Psychiatry, 2010, 71, 1475-1481.
206. Bobo, W.V.; Woodward, N.D.; Sim, M.Y.; Jayathilake, K.; Meltzer, H.Y. The effect of adjunctive armodafinil on cognitive performance and psychopathology in antipsychotic-treated patients with schizophrenia/schizoaffective disorder: a randomized, doubleblind, placebo-controlled trial. Schizophr. Res., 2011, 130, 106-113.
207. Kane, J.M.; Yang, R.; Youakim, J.M. Adjunctive armodafinil for negative symptoms in adults with schizophrenia: a double-blind, placebo-controlled study. Schizophr. Res., 2012, 135, 116-122.
208. Neubauer, D.N. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia. Curr. Opin. Invest. Drugs, 2010, 11, 101-110.